Trials / Completed
CompletedNCT05357911
A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
A Phase I, Single-center, Open-label, Fixed-sequence Study in Chinese Healthy Male Adults to Evaluate the Effect of AB-106 on the Pharmacokinetics of Digoxin
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Nuvation Bio Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
AB-106-C111 is China-only study, for investigating the drug interaction between AB-106 and P-gp substrate (Digoxin). （n=16）
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AB-106, digoxin | Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin |
Timeline
- Start date
- 2021-07-13
- Primary completion
- 2021-08-20
- Completion
- 2021-12-03
- First posted
- 2022-05-03
- Last updated
- 2024-11-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05357911. Inclusion in this directory is not an endorsement.